| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/25/2001 | CN1305490A Improved processing for preparing schift base adducts of amines with i(o)-hydroxy aldehydes and compositions of matter based thereon |
| 07/25/2001 | CN1305387A Enhancement of antibody-cytokine fusion protein medicated immune responses by co-administration with prostaglandin inhibitor |
| 07/25/2001 | CN1305386A Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 07/25/2001 | CN1305382A Use of PEG-IFN-alpha and triazole nucleoside for treatment of chronic hepatitis C |
| 07/25/2001 | CN1305371A Multiparticulate pharmaceutical form with programmed and timed release and preparation method |
| 07/25/2001 | CN1305369A Pharmaceutical aerosol formulation |
| 07/25/2001 | CN1305368A Implants for administering substances and methods of producing implants |
| 07/25/2001 | CN1305366A Cosmetic product |
| 07/25/2001 | CN1304773A Amphoteric diluent and disintegrating agent composition, its preparation method and use |
| 07/25/2001 | CN1068794C Solvent for saponin powder for injecta |
| 07/25/2001 | CN1068778C Drag composition for treating and curing and its preparing method |
| 07/24/2001 | US6265540 Peptide having specific amino acid sequence which is cleavage site for prostate specific antigen proteolytic activity; antiproliferative agents |
| 07/24/2001 | US6265449 Aqueous compositions comprising ranitidine and LCMT sucrose |
| 07/24/2001 | US6265444 Ophthalmic composition |
| 07/24/2001 | US6265392 Solubilizing agent and an antioxidant, wherein the solution has less than or equal to about 1 ppm of aluminum during the shelf life of the composition. |
| 07/24/2001 | US6265377 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 07/24/2001 | US6264990 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. |
| 07/24/2001 | US6264989 Spherical single-substance particles, medicines and foodstuffs containing the particles, and method of production thereof |
| 07/24/2001 | US6264988 Reduce bleeding time in animal |
| 07/24/2001 | US6264987 Method for preparing microparticles having a selected polymer molecular weight |
| 07/24/2001 | US6264984 Effervescent histamine H2 antagonist composition |
| 07/24/2001 | US6264983 Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| 07/24/2001 | US6264981 Oral transmucosal drug dosage using solid solution |
| 07/24/2001 | US6264980 Transdermal resorption of active substances from supercooled masses of levulic acid |
| 07/24/2001 | US6264975 Methods of hydrating mucosal surfaces |
| 07/24/2001 | US6264973 Apparatus and method for anesthetizing the cervical region of a female |
| 07/24/2001 | US6264970 Biodegradable polymer |
| 07/24/2001 | US6264961 Oil-water emulsifiers |
| 07/24/2001 | US6264943 Parkinson's disease |
| 07/24/2001 | US6264935 Hypotensive agent for eyes |
| 07/24/2001 | US6264927 Mixture of diethyl ether and iodine |
| 07/24/2001 | US6264920 Tunable indocyanine dyes for biomedical applications |
| 07/24/2001 | US6264917 Targeted ultrasound contrast agents |
| 07/24/2001 | US6264914 Contrast agents |
| 07/24/2001 | CA2331719A1 Rapidly disintegrating and fast-dissolving solid dosage form |
| 07/24/2001 | CA2285266C Extended release formulations of erythromycin derivatives |
| 07/24/2001 | CA2229184C Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| 07/24/2001 | CA2221753C Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 07/24/2001 | CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients |
| 07/24/2001 | CA2049822C Stable aqueous preparation |
| 07/24/2001 | CA2030773C Stabilized solutions of psychotropic agents |
| 07/21/2001 | CA2332468A1 Nanoemulsions containing amphiphilic lipids and an peg ester and its use |
| 07/19/2001 | WO2001051689A1 Biomolecules having multiple attachment moieties for binding to a substrate surface |
| 07/19/2001 | WO2001051558A1 Microgels and external preparations containing the same |
| 07/19/2001 | WO2001051524A1 Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects |
| 07/19/2001 | WO2001051510A2 G-csf conjugates |
| 07/19/2001 | WO2001051454A1 Compounds and compositions for delivering active agents |
| 07/19/2001 | WO2001051196A1 Templating of solid particles by polymer multilayers |
| 07/19/2001 | WO2001051092A2 Enhanced transport of agents using membrane disruptive agents |
| 07/19/2001 | WO2001051091A1 Bioconjugates and uses thereof |
| 07/19/2001 | WO2001051089A1 Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
| 07/19/2001 | WO2001051087A2 Novel treatment for eye disease |
| 07/19/2001 | WO2001051082A1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/19/2001 | WO2001051081A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | WO2001051073A2 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 07/19/2001 | WO2001051071A2 Transepithelial delivery of glp-1 derivatives |
| 07/19/2001 | WO2001051066A2 Reduction in bacterial colonization by administering bacteriophage compositions |
| 07/19/2001 | WO2001051065A1 Perfusion liquid preparations for ophthalmic operations |
| 07/19/2001 | WO2001051053A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 07/19/2001 | WO2001051050A1 Novel substituted benzimidazole dosage forms and method of using same |
| 07/19/2001 | WO2001051032A2 Micronized freeze-dried particles |
| 07/19/2001 | WO2001051028A2 Formulations and methods for administration of pharmacologically or biologically active compounds |
| 07/19/2001 | WO2001051027A2 Polymer blends as biodegradable matrices for preparing biocomposites |
| 07/19/2001 | WO2001051026A2 Instant granules and process for their formulation |
| 07/19/2001 | WO2001051024A2 Implantation kit comprising a support phase and a solvent |
| 07/19/2001 | WO2001051014A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | WO2001051008A2 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 07/19/2001 | WO2001051003A2 Use of lipid conjugates in the treatment of disease |
| 07/19/2001 | WO2001050994A1 Topical medicated bioadhesive compositions and methods of use and preparation thereof |
| 07/19/2001 | WO2001050873A1 Thickened oil compositions of edible oil |
| 07/19/2001 | WO2001050872A2 Method for produce sanitation using bacteriophages |
| 07/19/2001 | WO2001050866A2 Method and device for sanitation using bacteriophages |
| 07/19/2001 | WO2001050860A1 Improved topical drug delivery composition and method |
| 07/19/2001 | WO2001005361A3 Emulsifier-free finely dispersed systems of the oil-in-water type |
| 07/19/2001 | WO2001002020A3 Compositions and methods for targeted enzymatic release of cell regulatory compounds |
| 07/19/2001 | WO2000064485A9 Specifically targeted catalytic antagonists and uses thereof |
| 07/19/2001 | WO2000041474A3 Anti-cd3 immunotoxins and therapeutic uses therefor |
| 07/19/2001 | WO1999060869A8 Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 07/19/2001 | US20010008772 Lipid, nucleic acid complex |
| 07/19/2001 | US20010008771 Chimerical peptide-nucleic acid fragment, process for producing the same and its for appropriately introducing nucleic acids into cell organelles and cells |
| 07/19/2001 | US20010008759 Contacting target cells with member of antibody phage display library |
| 07/19/2001 | US20010008758 Electrosensitizing red blood cell; applying sound waves |
| 07/19/2001 | US20010008639 Reducing dosage; analgesics |
| 07/19/2001 | US20010008637 Water insolubility hydrophobic synthetic material |
| 07/19/2001 | US20010008632 Aqueous medicament preparations for the production of propellent gas-free aerosols |
| 07/19/2001 | DE19961340A1 Verfahren zur Emulsionspolymerisation von Olefinen The emulsion polymerization process of olefins |
| 07/19/2001 | DE19960206A1 Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung Complexation of RNA with polyethyleneimine for their stabilization and cellular infiltration |
| 07/19/2001 | DE19954245A1 Mehrschichtige filmförmige Zubereitung aus hydrophilen Polymeren zur schnellen Freisetzung von Wirkstoffen Multilayer film-form preparation of hydrophilic polymers for rapid release of active ingredients |
| 07/19/2001 | DE10000333A1 Pharmazeutische Zusammensetzung zur transdermalen Verabreichung von Hormonen mit einem permeationsverbessernden Zusatzstoff A pharmaceutical composition for transdermal delivery of hormones with an additive permeationsverbessernden |
| 07/19/2001 | CA2430501A1 Method for produce sanitation using bacteriophages |
| 07/19/2001 | CA2430500A1 Method and device for sanitation using bacteriophages |
| 07/19/2001 | CA2430498A1 Reduction in bacterial colonization by administering bacteriophage compositions |
| 07/19/2001 | CA2397386A1 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 07/19/2001 | CA2397091A1 Biomolecules having multiple attachment moieties for binding to a substrate surface |
| 07/19/2001 | CA2397068A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | CA2396384A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | CA2396237A1 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 07/19/2001 | CA2396071A1 Thickened oil compositions of edible oil |
| 07/19/2001 | CA2396044A1 Improved topical drug delivery composition and method |
| 07/19/2001 | CA2395567A1 Novel treatment for eye disease |